Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6-methylguanine-DNA methyltransferase promoter methylation in patients with gliomas

被引:27
作者
Zhang, Simin [2 ,3 ]
Sun, Huaiqiang [2 ]
Su, Xiaorui [2 ,3 ]
Yang, Xibiao [1 ,3 ,4 ]
Wang, Weina [2 ]
Wan, Xinyue [2 ]
Tan, Qiaoyue [2 ,5 ,6 ]
Chen, Ni [7 ]
Yue, Qiang [1 ,3 ,4 ]
Gong, Qiyong [2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Radiol, 37 GuoXue Xiang, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Funct & Mol Imaging Key Lab Sichuan Prov, Huaxi MR Res Ctr HMRRC,Dept Radiol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Huaxi Glioma Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Div Radiat Phys, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[7] Sichuan Univ, Dept Pathol, West China Hosp, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
automated machine learning; glioma; isocitrate dehydrogenase mutation; O-6‐ methylguanine‐ DNA methyltransferase promoter methylation; tree‐ based optimization tool; GRADE GLIOMA; GLIOBLASTOMA; FEATURES; TEMOZOLOMIDE; SURVIVAL; IDH1;
D O I
10.1002/jmri.27498
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Combining isocitrate dehydrogenase mutation (IDHmut) with O-6-methylguanine-DNA methyltransferase promoter methylation (MGMTmet) has been identified as a critical prognostic molecular marker for gliomas. The aim of this study was to determine the ability of glioma radiomics features from magnetic resonance imaging (MRI) to predict the co-occurrence of IDHmut and MGMTmet by applying the tree-based pipeline optimization tool (TPOT), an automated machine learning (autoML) approach. This was a retrospective study, in which 162 patients with gliomas were evaluated, including 58 patients with co-occurrence of IDHmut and MGMTmet and 104 patients with other status comprising: IDH wildtype and MGMT unmethylated (n = 67), IDH wildtype and MGMTmet (n = 36), and IDHmut and MGMT unmethylated (n = 1). Three-dimensional (3D) T1-weighted images, gadolinium-enhanced 3D T1-weighted images (Gd-3DT1WI), T2-weighted images, and fluid-attenuated inversion recovery (FLAIR) images acquired at 3.0 T were used. Radiomics features were extracted from FLAIR and Gd-3DT1WI images. The TPOT was employed to generate the best machine learning pipeline, which contains both feature selector and classifier, based on input feature sets. A 4-fold cross-validation was used to evaluate the performance of automatically generated models. For each iteration, the training set included 121 subjects, while the test set included 41 subjects. Student's t-test or a chi-square test was applied on different clinical characteristics between two groups. Sensitivity, specificity, accuracy, kappa score, and AUC were used to evaluate the performance of TPOT-generated models. Finally, we compared the above metrics of TPOT-generated models to identify the best-performing model. Patients' ages and grades between two groups were significantly different (p = 0.002 and p = 0.000, respectively). The 4-fold cross-validation showed that gradient boosting classifier trained on shape and textual features from the Laplacian-of-Gaussian-filtered Gd-3DT1 achieved the best performance (average sensitivity = 81.1%, average specificity = 94%, average accuracy = 89.4%, average kappa score = 0.76, average AUC = 0.951). Using autoML based on radiomics features from MRI, a high discriminatory accuracy was achieved for predicting co-occurrence of IDHmut and MGMTmet in gliomas. Level of Evidence 3 Technical Efficacy Stage 3
引用
收藏
页码:197 / 205
页数:9
相关论文
共 50 条
[21]   Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome [J].
Lalezari, Shadi ;
Chou, Arthur P. ;
Tran, Anh ;
Solis, Orestes E. ;
Khanlou, Negar ;
Chen, Weidong ;
Li, Sichen ;
Carrillo, Jose A. ;
Chowdhury, Reshmi ;
Selfridge, Julia ;
Sanchez, Desiree E. ;
Wilson, Ryan W. ;
Zurayk, Mira ;
Lalezari, Jonathan ;
Lou, Jerry J. ;
Ormiston, Laurel ;
Ancheta, Karen ;
Hanna, Robert ;
Miller, Paul ;
Piccioni, David ;
Ellingson, Benjamin M. ;
Buchanan, Colin ;
Mischel, Paul S. ;
Nghiemphu, Phioanh L. ;
Green, Richard ;
Wang, He-Jing ;
Pope, Whitney B. ;
Liau, Linda M. ;
Elashoff, Robert M. ;
Cloughesy, Timothy F. ;
Yong, William H. ;
Lai, Albert .
NEURO-ONCOLOGY, 2013, 15 (03) :370-381
[22]   O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas [J].
Koos, B. ;
Peetz-Dienhart, S. ;
Riesmeier, B. ;
Fruehwald, M. C. ;
Hasselblatt, M. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (04) :356-358
[23]   O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma [J].
Jens Jakob ;
Maren Hille ;
Christian Sauer ;
Philipp Ströbel ;
Frederik Wenz ;
Peter Hohenberger .
Radiation Oncology, 7
[24]   O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma [J].
Jakob, Jens ;
Hille, Maren ;
Sauer, Christian ;
Stroebel, Philipp ;
Wenz, Frederik ;
Hohenberger, Peter .
RADIATION ONCOLOGY, 2012, 7
[25]   Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients [J].
Fumagalli, Caterina ;
Pruneri, Giancarlo ;
Possanzini, Paola ;
Manzotti, Michela ;
Barile, Monica ;
Feroce, Irene ;
Colleoni, Marco ;
Bonanni, Bernardo ;
Maisonneuve, Patrick ;
Radice, Paolo ;
Viale, Giuseppe ;
Barberis, Massimo .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) :131-137
[26]   Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas [J].
Ochsenbein, Adrian F. ;
Schubert, Adrian D. ;
Vassella, Erik ;
Mariani, Luigi .
JOURNAL OF NEURO-ONCOLOGY, 2011, 103 (02) :343-351
[27]   Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma [J].
Jung, Tae-Young ;
Jung, Shin ;
Moon, Kyung-Sub ;
Kim, In-Young ;
Kang, Sam-Suk ;
Kim, Young-Hee ;
Park, Chang-Soo ;
Lee, Kyung-Hwa .
ONCOLOGY REPORTS, 2010, 23 (05) :1269-1276
[28]   Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients [J].
Chen, Xi ;
Yan, Yuanliang ;
Zhou, Jianhua ;
Huo, Lei ;
Qian, Long ;
Zeng, Shuangshuang ;
Li, Zhi ;
Wei, Jie ;
Xu, Zhijie ;
Gong, Zhicheng .
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (20)
[29]   O6-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current [J].
Suri, Vaishali ;
Jha, Prerana ;
Sharma, Mehar Chand ;
Sarkar, Chitra .
NEUROLOGY INDIA, 2011, 59 (02) :229-235
[30]   Clinical and Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Melanoma: A Systematic Meta-Analysis [J].
Qi, Fang ;
Yin, Zhiqi ;
Wang, Guangping ;
Zeng, Sanwu .
ANNALS OF DERMATOLOGY, 2018, 30 (02) :129-135